News

Niraparib Approved for Maintenance Treatment of Ovarian Cancer

Niraparib Approved for Maintenance Treatment of Ovarian Cancer

March 28, 2017

(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib is the first PARP inhibitor to be approved … Continued

Research

Research Updates from 2017 SGO Annual Meeting

Research Updates from 2017 SGO Annual Meeting

March 23, 2017

(March 23, 2017) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 11-14, 2017 in Maryland. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA … Continued

Research

Screening High-Risk Women Catches More Early Stage Ovarian ...

Screening High-Risk Women Catches More Early Stage Ovarian Cancers

March 15, 2017

(March 15, 2017) Results from a large study showed that screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the year after screening ended. However, it is not yet known whether this screening approach would improve survival in screened high-risk women. The results of the study … Continued

Research

Hormone Therapy Improves Survival of Low Grade Serous Carci...

Hormone Therapy Improves Survival of Low Grade Serous Carcinoma Patients

March 6, 2017

(March 6, 2017) A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr. Robert Coleman, published a study in Journal of Clinical Oncology about the effect of hormonal therapy on a rare type of ovarian cancer. The use of hormone maintenance therapy (HMT) with low-grade serous carcinoma (LGSC), … Continued

OCRA News

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

OCRFA Research Finds New Gene Mutation Spurs Cancer Growth

February 7, 2017

(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA … Continued

OCRA News

Rucaparib Extends PFS in Ovarian Cancer

Rucaparib Extends PFS in Ovarian Cancer

February 3, 2017

(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. The goal of the trial was to test if the efficacy of rucaparib, an oral PARP inhibitor, was dependent on the type of tumor mutation. … Continued

OCRA News

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer ...

OCRFA Funded Research Studies DNA Repair in Ovarian Cancer Cells

January 30, 2017

(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression of DNA damage repair in ovarian cancer cells. The EMSY gene is amplified in approximately … Continued

OCRA News

OCRFA Awards $5.6 Million in Scientific Research Grants for...

OCRFA Awards $5.6 Million in Scientific Research Grants for 2017

January 20, 2017

(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million. This year’s grants have been awarded to twenty top scientists at thirteen leading medical centers across the country. “Our 2017 grantees are among the best and brightest working … Continued

OCRA News

Now Accepting Applications for 2017 Community Partners

Now Accepting Applications for 2017 Community Partners

January 13, 2017

OCRFA’s Community Partners (formerly called Partner Members) are outstanding grassroots, local and national organizations around the country who share a commitment to eradicate ovarian cancer through research, advocacy, support, education and awareness. The goal of our Community Partners initiative is to unite the ovarian cancer community into a national movement speaking with one voice through … Continued

Community

Now Accepting Scholarship Applications for 2017 Ovarian Can...

Now Accepting Scholarship Applications for 2017 Ovarian Cancer National Conference

January 9, 2017

Update: The 2017 Scholarship Application closed on April 2, 2017. Our scholarship program allows patients and caregivers to learn about ovarian cancer and connect with others who share their experiences. In 2016, thanks to the generosity of donors, our scholarship program helped 40 individuals attend our National Conference. A limited number of scholarships for registration … Continued

Community

Give today to invest in tomorrow’s cure.

Give today to invest in tomorrow’s cure.

December 30, 2016

Time is running out to make your tax-deductible 2016 gift to OCRFA. We need your help. Over 22,000 women will be diagnosed with ovarian cancer in 2017. Over 200,000 women are currently living with ovarian cancer. Your support will make a big difference in the lives of these women and their families. Ovarian cancer is … Continued

OCRA News

Fighting Ovarian Cancer Through Patient Support and Education

Fighting Ovarian Cancer Through Patient Support and Education

December 22, 2016

Every year, 22,000 women are newly diagnosed with ovarian cancer. As OCRFA strives toward a cure and better treatments through research, we also provide patients and survivors with the care they need through our support and education programs. Now in 29 sites across the country, our Woman to Woman program has impacted over 400 women, … Continued

Community